Activation of overexpressed glucagon‐like peptide‐1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression

Abstract Aims/Introduction Incretin therapy is a common treatment for type 2 diabetes mellitus. We have previously reported an anti‐prostate cancer effect of glucagon‐like peptide‐1 receptor (GLP‐1R) agonist exendin‐4. The attenuation of cell proliferation in the prostate cancer cell line was depend...

Descripció completa

Dades bibliogràfiques

Autors principals:	Toru Shigeoka, Takashi Nomiyama, Takako Kawanami, Yuriko Hamaguchi, Tsuyoshi Horikawa, Tomoko Tanaka, Shinichiro Irie, Ryoko Motonaga, Nobuya Hamanoue, Makito Tanabe, Kazuki Nabeshima, Masatoshi Tanaka, Toshihiko Yanase, Daiji Kawanami
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2020-09-01
Col·lecció:	Journal of Diabetes Investigation
Matèries:	Cell cycle Glucagon‐like peptide‐1 receptor Prostate cancer
Accés en línia:	https://doi.org/10.1111/jdi.13247
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!